Edition:
United States

Galapagos NV (GLPG.AS)

GLPG.AS on Amsterdam Stock Exchange

91.20EUR
18 Feb 2019
Change (% chg)

-- (--)
Prev Close
€91.20
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
424,700
52-wk High
€105.35
52-wk Low
€70.64

Chart for

About

Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and... (more)

Overall

Beta: 1.52
Market Cap(Mil.): €4,940.01
Shares Outstanding(Mil.): 54.47
Dividend: --
Yield (%): --

Financials

  GLPG.AS Industry Sector
P/E (TTM): -- 88.11 35.99
EPS (TTM): -1.47 -- --
ROI: -6.19 10.12 12.72
ROE: -6.66 10.40 13.73

BRIEF-Galapagos And Fibrocor Sign Partnership Focusing On Fibrosis

* SAID ON FRIDAY FIBROCOR THERAPEUTICS L.P. AND GALAPAGOS SIGN PARTNERSHIP FOCUSING ON FIBROSIS

Jan 07 2019

Rheinmetall says in talks to buy stake in rival Krauss-Maffei

FRANKFURT Rheinmetall on Monday said it was in talks about buying a stake in rival KMW and Nexter Defense Systems N.V, sending shares in the defense company sharply higher.

Nov 26 2018

Rheinmetall says in talks to buy stake in rival Krauss-Maffei

FRANKFURT, Nov 26 Rheinmetall on Monday said it was in talks about buying a stake in rival KMW and Nexter Defense Systems N.V, sending shares in the defense company sharply higher.

Nov 26 2018

BRIEF-Galapagos Increases Share Capital Through Warrant Exercises

* ANNOUNCED ON FRIDAY A SHARE CAPITAL INCREASE ARISING FROM WARRANT EXERCISES

Nov 26 2018

BRIEF-Galapagos Reports Top-line Interim Results Of FALCON Trial Part 1 In CF

* REPORTED ON WEDNESDAY TOPLINE INTERIM RESULTS OF FALCON TRIAL PART 1 IN CF

Oct 25 2018

BRIEF-Galapagos 9-Month Revenue Rises To 205.1 Million Euros

* REPORTED ON WEDNESDAY 9-MONTH GROUP REVENUES INCREASED BY EUR 98.7 MILLION TO EUR 205.1 MILLION

Oct 25 2018

BRIEF-Galapagos Phase 3 Data On Filgotinib In Biologic-Experienced Rheumatoid Arthritis

* REPORTED TOGETHER WITH GILEAD SCIENCES ON SUNDAY PHASE 3 DATA ON FILGOTINIB IN BIOLOGIC-EXPERIENCED RHEUMATOID ARTHRITIS

Oct 22 2018

BRIEF-Galapagos: Capital Increase Of EUR 2.0 Million

* ANNOUNCED ON WEDNESDAY SHARE CAPITAL INCREASE THROUGH WARRANT EXERCISES

Oct 04 2018

UPDATE 1-Galapagos, Gilead bask in $4-6 bln new drug sales hope

LONDON, Sept 12 Strong results for an experimental drug that promises to disrupt the rheumatoid arthritis market lifted shares in Belgian-Dutch firm Galapagos to an all-time high on Wednesday, as analysts forecast multibillion-dollar sales.

Sep 12 2018

Galapagos shares soar on $4-6 billion hopes for new drug

LONDON Strong results for an experimental drug that promises to disrupt the rheumatoid arthritis market lifted shares in Belgian-Dutch firm Galapagos to an all-time high on Wednesday, as analysts forecast multibillion-dollar sales.

Sep 12 2018

Earnings vs. Estimates